EATONTOWN, N.J. – (GlobeNewsWire) – September 25, 2013- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the opening of three new adipose tissue (fat) collection centers at Dr. Park Avenue’s NJ locations. Dr. Park Avenue is a leading provider of aesthetic and cosmetic services in the Tri-State area with locations in Brick Township, Franklin Lakes and Hoboken, New Jersey.
Dr. Park Avenue’s newest center, conveniently located at 44 Hudson Place in Hoboken, is scheduled for its grand opening Saturday, September 28, 2013. In conjunction with the opening, Dr. Park Avenue will formally introduce American CryoStem’s ATGRAFT™ fat storage service for patients interested in fat grafting as an alternative to artificial fillers by using their own stored fat tissue to undergo transfer procedures to the face, hands, breast, and buttocks.
With one liposuction, patients can store their excess body fat as a natural filler for immediate or future use in cosmetic enhancement procedures. Fat transfers have been used for many years to fill in facial flaws, such as hollowed cheeks, sunken eyes, indented scars or to repair surgical defects. Today, new fat transfer techniques (also known as fat grafting) are used to augment many other areas of the body, including the hands, face, buttocks, biceps, triceps, and breasts. Consequently, demand for natural fillers is on the rise increasing the need for preserving fat tissue in a safe, secure storage environment.
Renowned Surgeon Dr. Paul Fondacaro, Founder and Medical Director of Dr. Park Avenue, stated, “I firmly believe that the future of cosmetic medicine is going to rely on the principles of fat storage. When a patient stores his or her own fat tissue, it allows us to plan ahead, set a schedule of grafts or transfers and optimize the patient’s procedures to achieve the patient’s desired results. All of this is accomplished with a single tissue harvest, which allows multiple layered fat transfers in the future, eliminating the need for further liposuctions. Moreover, by teaming with American CryoStem, we are assured that our patients’ tissue is stored in an FDA registered, cGMP compliant human tissue processing and cryo-storage facility that promotes the highest possible clinical standards.”
Customers of American CryoStem’s ATGRAFT™ tissue storage services also have additional opportunities to further process portions of their clinically prepared adipose tissue samples for future uses in Regenerative Medicine therapies and/or to create personalized skin care products made from their own adult stem cell growth factors.
Physicians that would like to offer ATGRAFT™ tissue storage services to patients should call 732-747-1007 or email firstname.lastname@example.org for an informational kit.
About American CryoStem Corporation A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking, and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey.
For more information, please visit www.americancryostem.com and www.acslaboratories.com.
Forward Looking Statements This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.